HSPB1 inhibits the endothelial-to-mesenchymal transition to suppress pulmonary fibrosis and lung tumorigenesis

Seo Hyun Choi, Jae Kyung Nam, Bu Yeo Kim, Junho Jang, Young Bae Jin, Hae June Lee, Seungwoo Park, Young Hoon Ji, Jaeho Cho, Yoon Jin Lee

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The endothelial-to-mesenchymal transition (EndMT) contributes to cancer, fibrosis, and other pathologic processes. However, the underlying mechanisms are poorly understood. Endothelial HSP1 (HSPB1) protects against cellular stress and has been implicated in cancer progression and pulmonary fibrosis. In this study, we investigated the role of HSPB1 in mediating the EndMT during the development of pulmonary fibrosis and lung cancer. HSPB1 silencing in human pulmonary endothelial cells accelerated emergence of the fibrotic phenotype after treatment with TGFβ or other cytokines linked to pulmonary fibrosis, suggesting that HSPB1 maintains endothelial cell identity. In mice, endothelial-specific overexpression of HSPB1 was sufficient to inhibit pulmonary fibrosis by blocking the EndMT. Conversely, HSPB1 depletion in a mouse model of lung tumorigenesis induced the EndMT. In clinical specimens of non-small cell lung cancer, HSPB1 expression was absent from tumor endothelial cells undergoing the EndMT. Our results showed that HSPB1 regulated the EndMT in lung fibrosis and cancer, suggesting that HSPB1-targeted therapeutic strategies may be applicable for treating an array of fibrotic diseases.

Original languageEnglish
Pages (from-to)1019-1030
Number of pages12
JournalCancer Research
Volume76
Issue number5
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Pulmonary Fibrosis
Carcinogenesis
Lung Neoplasms
Lung
Endothelial Cells
Fibrosis
Neoplasms
Pathologic Processes
Non-Small Cell Lung Carcinoma
Cytokines
Phenotype
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Choi, S. H., Nam, J. K., Kim, B. Y., Jang, J., Jin, Y. B., Lee, H. J., ... Lee, Y. J. (2016). HSPB1 inhibits the endothelial-to-mesenchymal transition to suppress pulmonary fibrosis and lung tumorigenesis. Cancer Research, 76(5), 1019-1030. https://doi.org/10.1158/0008-5472.CAN-15-0952
Choi, Seo Hyun ; Nam, Jae Kyung ; Kim, Bu Yeo ; Jang, Junho ; Jin, Young Bae ; Lee, Hae June ; Park, Seungwoo ; Ji, Young Hoon ; Cho, Jaeho ; Lee, Yoon Jin. / HSPB1 inhibits the endothelial-to-mesenchymal transition to suppress pulmonary fibrosis and lung tumorigenesis. In: Cancer Research. 2016 ; Vol. 76, No. 5. pp. 1019-1030.
@article{5ecf3b5ae3be41079934d43d465e8f12,
title = "HSPB1 inhibits the endothelial-to-mesenchymal transition to suppress pulmonary fibrosis and lung tumorigenesis",
abstract = "The endothelial-to-mesenchymal transition (EndMT) contributes to cancer, fibrosis, and other pathologic processes. However, the underlying mechanisms are poorly understood. Endothelial HSP1 (HSPB1) protects against cellular stress and has been implicated in cancer progression and pulmonary fibrosis. In this study, we investigated the role of HSPB1 in mediating the EndMT during the development of pulmonary fibrosis and lung cancer. HSPB1 silencing in human pulmonary endothelial cells accelerated emergence of the fibrotic phenotype after treatment with TGFβ or other cytokines linked to pulmonary fibrosis, suggesting that HSPB1 maintains endothelial cell identity. In mice, endothelial-specific overexpression of HSPB1 was sufficient to inhibit pulmonary fibrosis by blocking the EndMT. Conversely, HSPB1 depletion in a mouse model of lung tumorigenesis induced the EndMT. In clinical specimens of non-small cell lung cancer, HSPB1 expression was absent from tumor endothelial cells undergoing the EndMT. Our results showed that HSPB1 regulated the EndMT in lung fibrosis and cancer, suggesting that HSPB1-targeted therapeutic strategies may be applicable for treating an array of fibrotic diseases.",
author = "Choi, {Seo Hyun} and Nam, {Jae Kyung} and Kim, {Bu Yeo} and Junho Jang and Jin, {Young Bae} and Lee, {Hae June} and Seungwoo Park and Ji, {Young Hoon} and Jaeho Cho and Lee, {Yoon Jin}",
year = "2016",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-15-0952",
language = "English",
volume = "76",
pages = "1019--1030",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

Choi, SH, Nam, JK, Kim, BY, Jang, J, Jin, YB, Lee, HJ, Park, S, Ji, YH, Cho, J & Lee, YJ 2016, 'HSPB1 inhibits the endothelial-to-mesenchymal transition to suppress pulmonary fibrosis and lung tumorigenesis', Cancer Research, vol. 76, no. 5, pp. 1019-1030. https://doi.org/10.1158/0008-5472.CAN-15-0952

HSPB1 inhibits the endothelial-to-mesenchymal transition to suppress pulmonary fibrosis and lung tumorigenesis. / Choi, Seo Hyun; Nam, Jae Kyung; Kim, Bu Yeo; Jang, Junho; Jin, Young Bae; Lee, Hae June; Park, Seungwoo; Ji, Young Hoon; Cho, Jaeho; Lee, Yoon Jin.

In: Cancer Research, Vol. 76, No. 5, 01.03.2016, p. 1019-1030.

Research output: Contribution to journalArticle

TY - JOUR

T1 - HSPB1 inhibits the endothelial-to-mesenchymal transition to suppress pulmonary fibrosis and lung tumorigenesis

AU - Choi, Seo Hyun

AU - Nam, Jae Kyung

AU - Kim, Bu Yeo

AU - Jang, Junho

AU - Jin, Young Bae

AU - Lee, Hae June

AU - Park, Seungwoo

AU - Ji, Young Hoon

AU - Cho, Jaeho

AU - Lee, Yoon Jin

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The endothelial-to-mesenchymal transition (EndMT) contributes to cancer, fibrosis, and other pathologic processes. However, the underlying mechanisms are poorly understood. Endothelial HSP1 (HSPB1) protects against cellular stress and has been implicated in cancer progression and pulmonary fibrosis. In this study, we investigated the role of HSPB1 in mediating the EndMT during the development of pulmonary fibrosis and lung cancer. HSPB1 silencing in human pulmonary endothelial cells accelerated emergence of the fibrotic phenotype after treatment with TGFβ or other cytokines linked to pulmonary fibrosis, suggesting that HSPB1 maintains endothelial cell identity. In mice, endothelial-specific overexpression of HSPB1 was sufficient to inhibit pulmonary fibrosis by blocking the EndMT. Conversely, HSPB1 depletion in a mouse model of lung tumorigenesis induced the EndMT. In clinical specimens of non-small cell lung cancer, HSPB1 expression was absent from tumor endothelial cells undergoing the EndMT. Our results showed that HSPB1 regulated the EndMT in lung fibrosis and cancer, suggesting that HSPB1-targeted therapeutic strategies may be applicable for treating an array of fibrotic diseases.

AB - The endothelial-to-mesenchymal transition (EndMT) contributes to cancer, fibrosis, and other pathologic processes. However, the underlying mechanisms are poorly understood. Endothelial HSP1 (HSPB1) protects against cellular stress and has been implicated in cancer progression and pulmonary fibrosis. In this study, we investigated the role of HSPB1 in mediating the EndMT during the development of pulmonary fibrosis and lung cancer. HSPB1 silencing in human pulmonary endothelial cells accelerated emergence of the fibrotic phenotype after treatment with TGFβ or other cytokines linked to pulmonary fibrosis, suggesting that HSPB1 maintains endothelial cell identity. In mice, endothelial-specific overexpression of HSPB1 was sufficient to inhibit pulmonary fibrosis by blocking the EndMT. Conversely, HSPB1 depletion in a mouse model of lung tumorigenesis induced the EndMT. In clinical specimens of non-small cell lung cancer, HSPB1 expression was absent from tumor endothelial cells undergoing the EndMT. Our results showed that HSPB1 regulated the EndMT in lung fibrosis and cancer, suggesting that HSPB1-targeted therapeutic strategies may be applicable for treating an array of fibrotic diseases.

UR - http://www.scopus.com/inward/record.url?scp=84961842162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961842162&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-0952

DO - 10.1158/0008-5472.CAN-15-0952

M3 - Article

C2 - 26744531

AN - SCOPUS:84961842162

VL - 76

SP - 1019

EP - 1030

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 5

ER -